PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE

Myelodysplastic Syndrome

Fred Hutchinson Cancer CenterCell therapyPhase 2/3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 81/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
BUSULFANUM Sawa Ito, MD	Phase 4	BB
Daunomycin OHSU Knight Cancer Institute	Phase 3	BB
Cytarabine The First Affiliated Hospital of Soochow University	Phase 4	BB

View all 50 →

Same molecule, other indications

PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE is also rated in:

acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 2/3

74 / 100

graft versus host diseaseDormant

BB

Indicative · Phase 2/3

67 / 100

chronic myeloid leukemiaDormant

BB

Indicative · Phase 2

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.